Analyst Weekly, November 3, 2025
Commerce Diplomacy: US’s “Asia Blitz” Targets China
Whereas D.C. argued over spending, the US administration was busy redrawing Asia’s commerce map. Offers had been executed with Malaysia, Cambodia, Vietnam, and Thailand, all carrying provisions designed to curb China’s affect, from banning items made with pressured labor to tightening export controls on delicate applied sciences.
On the similar time, Washington and Beijing reached a one-year “managed decoupling” truce: China paused new rare-earth export bans, the US delayed new sanctions on Chinese language corporations, and either side agreed to extra agricultural and vitality commerce. The aim, at the very least for now, is to sluggish the financial separation with out derailing international provide chains.
Investor Takeaway: Anticipate renewed momentum in “China-plus-one” commerce beneficiaries like Vietnam, Thailand, and India. ETFs monitoring rising Asian manufacturing might achieve from redirected provide chains. US semiconductor and vitality exporters additionally stand to learn as commerce flows rebalance.
Allies within the Fold: Japan, South Korea, and the AI Angle
The US additionally deepened its alliances with Japan and South Korea, hanging funding pacts throughout nuclear vitality, shipbuilding, and synthetic intelligence (AI). Japan dedicated to assist finance $80 billion value of US nuclear tasks, whereas South Korea’s $350 billion funding plan, a long-debated package deal, will now prioritize heavy manufacturing and maritime industries.
In the meantime, tech cooperation took heart stage: Washington and Tokyo agreed to coordinate AI and quantum computing improvement, guaranteeing that allies depend on US-made AI chips. Taiwan additionally reported “progress” in its personal commerce talks, reinforcing America’s expertise sphere of affect.
Investor Takeaway: This “friendshoring” momentum is bullish for AI infrastructure and chipmakers tied to US provide chains. Names in semiconductors, clear vitality, and industrial robotics might see sustained demand. Lengthy-term buyers may have a look at international thematic funds targeted on AI or next-gen manufacturing.
Key Earnings Reviews: Week of November 3, 2025
Palantir Applied sciences (PLTR): Traders can be laser-focused on the uptake of Palantir’s new Synthetic Intelligence Platform (AIP) and its position in accelerating the corporate’s development. The increasing industrial use-cases for Palantir’s AI-driven analytics have analysts predicting a ~50% YoY income soar, underscoring the view that Palantir is on the forefront of the AI revolution.
Pfizer (PFE): Traders can be awaiting steering and new product momentum, in search of indicators that Pfizer’s non-COVID portfolio (which grew 14% within the prior 12 months’s quarter) can offset the steep decline in COVID franchise gross sales and restore earnings development.
Superior Micro Gadgets (AMD): Wall Road is targeted on momentum in AMD’s increasing AI and cloud segments, anticipating ~27% YoY gross sales development fueled by demand for EPYC server processors and new AI accelerators; a development buyers hope can preserve AMD’s 2025 rally intact within the face of PC market headwinds.
Uber Applied sciences (UBER): The highlight is on execution and margin self-discipline as Uber strives for sustainable profitability throughout rides and supply. Traders are awaiting regular ride-hailing revenue margins and enhancing unit economics in meals supply; strong bookings development coupled with value management might lengthen Uber’s 2025 inventory surge, whereas any slip in effectivity or demand would elevate doubts about its post-pandemic revenue trajectory.
BP (BP): The main target can be on money movement and strategic portfolio strikes amid an unsure oil worth outlook. Traders are eager for updates on BP’s plan to promote its Castrol lubricants unit, a divestment geared toward boosting shareholder worth, and can scrutinize how increased refining margins (anticipated to carry quarterly earnings) are balancing out softer upstream earnings.
Qualcomm (QCOM): Qualcomm’s report will check whether or not rising development areas can overcome weak spot in its core smartphone chip enterprise. Traders will gauge if demand for Qualcomm’s AI-enabled chips and enlargement into PCs, autos, and IoT can offset continued softness in international handset gross sales, the smartphone market stays Qualcomm’s stronghold however has been sluggish, so any commentary on handset demand or diversification (e.g. wins in premium telephones or PC processors) will seemingly drive the inventory’s response.
Shopify (SHOP): The e-commerce platform’s valuation rests on balancing speedy development with enhancing profitability. The important thing metric can be Shopify’s gross merchandise quantity (GMV) and income development (guided within the high-20% vary) relative to its expense self-discipline, buyers wish to see continued 20%+ GMV enlargement alongside proof that latest value cuts are boosting margins and free money movement, which might validate Shopify’s post-rally valuation.
McDonald’s (MCD): The fast-food large’s same-store gross sales combine is the crucial focus this quarter. Traders are watching how profitable McDonald’s new worth meal promotions have been in driving buyer visitors versus their impression on common test measurement; early analyst insights counsel the September launch of Further Worth Meals seemingly lifted foot visitors however dented common ticket, so the corporate’s comparable gross sales (anticipated ~+2.5% YoY) and administration’s commentary on pricing will set the post-earnings tone.
Novo Nordisk (NVO): The Danish pharma heavyweight’s outcomes will hinge on its blockbuster weight problems and diabetes medicine. Ozempic and Wegovy now account for roughly 65% of Novo Nordisk’s gross sales, so buyers can be laser-focused on the quarterly income from these GLP-1 medicines. Any replace on demand vs. provide constraints for Wegovy, and Novo’s potential to maintain excessive development within the face of recent opponents, can be pivotal in driving the inventory’s response.
Moderna (MRNA): Moderna’s narrative is shifting from COVID windfall to pipeline promise. With COVID-19 vaccine income sharply down, the important thing for buyers is any signal of stabilization in booster demand and progress in Moderna’s non-COVID pipeline. Specifically, updates on the uptake of its new fall COVID booster and the standing of upcoming vaccines (like RSV or flu) are essential – the market needs reassurance that Moderna’s subsequent technology of merchandise can fill the hole as COVID gross sales fade.
AstraZeneca (AZN): As a UK-based pharma large reporting this week, AstraZeneca’s core oncology and uncommon illness drug gross sales would be the focus. Traders are significantly tuned to development developments for key most cancers therapies and the corporate’s outlook amid upcoming drug patent expirations. Any updates on its pipeline (particularly in areas like oncology and the burgeoning diabetes/weight problems market) and the way it navigates drug pricing pressures within the US and Europe will seemingly drive AstraZeneca’s shares following earnings.
Airbnb (ABNB): The house-sharing platform’s quarter will activate the power of journey demand and reserving developments. The metric to observe is nights booked and common each day charges, as Airbnb has been posting round 8 to 10% income development. Traders can be listening to administration’s commentary on reserving momentum into the vacations and any alerts of shopper journey urge for food or margin strain – it will decide if Airbnb can preserve its post-pandemic development trajectory and excessive profitability into 2026.
Amgen (AMGN): As a newly inducted Dow element, Amgen’s story is about new medicine changing outdated ones. The main target is on whether or not Amgen’s lineup of newer therapies and its Horizon Pharma acquisition are producing sufficient development to offset patent fades and biosimilar competitors on getting older blockbusters. Traders will parse Amgen’s earnings and steering for proof that its progressive medicine (and value cuts) are driving income good points, a key issue behind Amgen’s market-beating efficiency this 12 months, as it will decide if the inventory’s outperformance can proceed.
Market Pulse: Vol, Skew, and a GLD Hangover
Regardless of political noise, the S&P 500 traded sideways by way of the heaviest stretch of earnings. Volatility cooled as earnings rolled on, with the VIX slipping beneath mid-October highs. Huge Tech earnings had been blended: Meta and Microsoft slipped, whereas Google held up. A big gold name place that had pushed months of upside was lower, signaling that the metallic’s 2025 rally could have peaked.
Volatility stays inverted, with near-term possibility costs increased than long-term ones; a setup that often normalizes as earnings move.
Investor Takeaway: With short-term volatility easing, broader fairness participation might resume, suppose mid-caps and worth shares. As gold cools, funds could rotate into equities or bonds. Traders in search of diversification may rebalance out of treasured metals and into dividend ETFs or high quality cyclical names.
Palantir: Sturdy Rally, Excessive Expectations Forward of Q3 Earnings
Palantir Applied sciences is about to report its Q3 earnings after the shut on Monday. The corporate, which makes a speciality of knowledge analytics and software program platforms, now ranks among the many 20 most respected corporations within the S&P 500. The inventory has surged greater than 160% this 12 months.
The market is at the moment in a brand new upward impulse, with the long-term uptrend confirmed by a contemporary document excessive final week. Within the short-term the inventory seems barely overbought, because the RSI sits above 70. With a ahead P/E above 260, the elemental valuation could be very excessive, rising the danger of a correction. Even minor disappointments might set off vital volatility.
Analysts anticipate Palantir’s income to have risen 50.5% year-over-year to $1.09 billion within the third quarter, whereas earnings per share are projected to have grown by 67.4% over the identical interval. Ought to the inventory come beneath strain within the coming days or even weeks, there are two key help zones (Honest Worth Gaps) to observe:
$171.26 to $172.84 – a zone examined 3 times already, with patrons defending it every time.
$160.87 to $161.06 – a deeper help space that would come into focus if a correction unfolds.
Palantir, weekly chart. Supply: eToro
Novo Nordisk: Can Q3 Outcomes Forestall Additional Losses?
Novo Nordisk will report its third-quarter outcomes on Wednesday earlier than the European market opens. The inventory has been in a downtrend for over a 12 months and has misplaced round 70% of its worth because the document excessive in July 2024.
In July and August, the share worth reacted to a long-term help zone (Honest Worth Hole) between 290 and 310 DKK, which dates again to the 2021 rally. Nevertheless, this response alone wasn’t sufficient to set off a sustained development reversal. Though there was a short-term rebound, solely a break above resistance at 463 DKK would considerably enhance the technical image.
The upcoming earnings report will seemingly be decisive, displaying whether or not Novo Nordisk will proceed its downward trajectory or if the long-term help space provides an opportunity for a backside formation.
Analysts anticipate income within the third quarter to have risen 7.9% year-on-year to 76.9 billion DKK, whereas earnings per share are projected to fall 19.1% to 4.95 DKK.
Novo Nordisk, weekly chart. Supply: eToro
This communication is for info and schooling functions solely and shouldn’t be taken as funding recommendation, a private advice, or a proposal of, or solicitation to purchase or promote, any monetary devices. This materials has been ready with out considering any specific recipient’s funding goals or monetary scenario and has not been ready in accordance with the authorized and regulatory necessities to advertise unbiased analysis. Any references to previous or future efficiency of a monetary instrument, index or a packaged funding product usually are not, and shouldn’t be taken as, a dependable indicator of future outcomes. eToro makes no illustration and assumes no legal responsibility as to the accuracy or completeness of the content material of this publication.
